Jill Carroll Biography and Net Worth

Director of Arcellx

Jill is a Partner at SR One. Previously, Jill’s background is in corporate development and partnering in biotech companies, including Dynavax Technologies (NASDAQ: DVAX). Jill also worked as a consultant, specializing in health care. Jill is a member of the Board of Directors of HotSpot Therapeutics and Odyssey Therapeutics. Jill received her BS from Duke University and her MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

What is Jill Carroll's net worth?: The estimated net worth of Jill Carroll is at least $129.01 million as of March 21st, 2024. Ms. Carroll owns 1,479,148 shares of Arcellx stock worth more than $129,011,289 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Carroll may own. Learn More about Jill Carroll's net worth.
How do I contact Jill Carroll?: The corporate mailing address for Ms. Carroll and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Jill Carroll's contact information.
Has Jill Carroll been buying or selling shares of Arcellx?: Jill Carroll has not been actively trading shares of Arcellx within the last three months. Most recently, Jill Carroll sold 504,263 shares of the business's stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $70.55, for a transaction totalling $35,575,754.65. Following the completion of the sale, the director now directly owns 1,479,148 shares of the company's stock, valued at $104,353,891.40. Learn More on Jill Carroll's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 29 times. They sold a total of 852,221 shares worth more than $59,596,182.56. The most recent insider tranaction occured on November, 11th when Director Kavita Patel sold 15,238 shares worth more than $1,614,008.96. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 11/11/2024.

Jill Carroll Insider Trading History at Arcellx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/21/2024	Sell	504,263	$70.55	$35,575,754.65	1,479,148
5/31/2023	Sell	315,164	$41.50	$13,079,306.00	2,513,230
5/11/2023	Sell	638,417	$45.01	$28,735,149.17	2,828,394

Jill Carroll Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $87.22

$83.69

$88.30

50 Day Range

MA: $86.52

$74.40

$106.53

2 Week Range

Now: $87.22

$46.42

$107.37

Volume

344,951 shs

Average Volume

481,359 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.